Dan Teleman

Dan Teleman has a diverse work experience in various roles and industries. Dan is currently the Chief Executive Officer at Pharma Two B since May 2023. Prior to this, they were the President at the same company from October 2022 to May 2023. Dan also serves as a Board Member at 4C Biomed since January 2023. Previously, they worked as an Executive Partner at Israel Biotech Fund from May 2022 to May 2023 and as the Chairman of the Board at Tamarix Pharma from July 2021 to May 2023. Earlier in their career, they were the CEO of Atox Bio from January 2010 to May 2022 and the CEO of PainReform from October 2007 to January 2010. Dan also held positions such as Director of Business Development at Pharmos from August 2005 to September 2007 and Product Manager at Amgen from June 2003 to June 2005. Prior to transitioning to the private sector, they worked as a Department Head at the Israel Defense Forces from April 1995 to June 2001.

Dan Teleman earned a Bachelor of Science (BSc) degree in Chemical Engineering from Ben-Gurion University of the Negev in 1994. Dan then went on to complete a Master of Science (MSc) degree in Biochemical Engineering from the same university, graduating in 1999. In 2003, Dan Teleman pursued further education and attained a Master of Business Administration (MBA) degree from Duke University - The Fuqua School of Business.